Pfizer reports positive COVID-19 vaccine results from booster in ages 5-11
Pfizer today announced positive results from a clinical trial evaluating the safety and efficacy of its COVID-19 vaccine booster dose in children aged 5-11, and said it plans to ask the Food and Drug Administration to authorize the booster for emergency use in this age group. The trial included 140 children who received the booster about 6 months after completing the primary vaccine series. The company said the booster was well tolerated and produced a strong immune response.
Related News Articles
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…